Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
about
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
description
2017 nî lūn-bûn
@nan
2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
name
Dual MET and ERBB inhibition o ...... mall-cell lung cancer (NSCLC).
@en
Dual MET and ERBB inhibition o ...... ced non-small-cell lung cancer
@nl
type
label
Dual MET and ERBB inhibition o ...... mall-cell lung cancer (NSCLC).
@en
Dual MET and ERBB inhibition o ...... ced non-small-cell lung cancer
@nl
prefLabel
Dual MET and ERBB inhibition o ...... mall-cell lung cancer (NSCLC).
@en
Dual MET and ERBB inhibition o ...... ced non-small-cell lung cancer
@nl
P2093
P2860
P50
P356
P1433
P1476
Dual MET and ERBB inhibition o ...... small-cell lung cancer (NSCLC)
@en
P2093
A Guillaumet-Adkins
A Martinez de Castro
A Martinez-Marti
A Villanueva
G Rodriguez-Esteban
J M Miquel
P2860
P304
P356
10.1093/ANNONC/MDX396
P577
2017-10-01T00:00:00Z